Motley Fool Premium
  1. Stocks
    2. /
  2. AstraZeneca Plc (LSE: AZN)
    3. /

LSE:AZN (AstraZeneca Plc)

About AZN

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Financial Market Data copyright © 2026 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.

AstraZeneca Plc (LSE: AZN) Latest News

Investing Articles

Who Can Pfizer Inc. Afford?

| Lisa Walls-Hester

Are Bristol-Myers Squibb Co (NYSE: BMY) or Shire PLC (LON:SHP) on Pfizer Inc. (NYSE:PFE)'s shopping list?

Read more »

Investing Articles

Why Do People Care If One Company Buys Another?

| Harvey Jones

Who cares if Pfizer wants to buy AstraZeneca plc (LON:AZN)? We all do, says Harvey Jones

Read more »

Investing Articles

AstraZeneca plc: Time To Cash In?

| Alessandro Pasetti

There are several reasons why Astra (LON:AZN) investors may want to cash in now, argues Alessandro Pasetti

Read more »

Investing Articles

What Should AstraZeneca plc Shareholders Learn From Failed Pfizer Bid?

| Roland Head

AstraZeneca plc (LON:AZN) shareholders should be happy, despite Pfizer's failure, says Roland Head.

Read more »

Investing Articles

How Much Lower Can AstraZeneca plc Go?

| Rupert Hargreaves

Will AstraZeneca plc's (LON:AZN) shares continue to fall?

Read more »

Company Comment

Lessons From The Great Investors… On Coca-Cola And AstraZeneca plc

| Mark Stones

AstraZeneca plc (LON: AZN) and Coca-Cola are the quintessential investments of two of the all-time greats.

Read more »

Company Comment

What You Need To Know About AstraZeneca plc Rejecting Pfizer’s Final Offer

| Mark Stones

AstraZeneca plc (LON: AZN) will live on as a standalone entity with ambitious revenue targets and a buzzing drugs pipeline.

Read more »

Investing Articles

Investors Should Be Careful Around AstraZeneca plc

| Rupert Hargreaves

With opposition against the Pfizer-AstraZeneca plc (LON: AZN) deal growing, investors need to be careful.

Read more »

Investing Articles

How AstraZeneca plc Could Struggle To Repeat A 5-Year Gain of 78%

| G A Chester

AstraZeneca plc (LON:AZN) could loose a third of its value in the next five years.

Read more »

Investing Articles

AstraZeneca plc Is In Play And I’m Holding Out For More

| Malcolm Wheatley

What might be the impact on your wealth if Pizfer buys AstraZeneca plc (LON:AZN)?

Read more »

Investing Articles

What Could Pfizer-AstraZeneca Be Like?

| Prabhat Sakya

What might be the positives from this potential takeover?

Read more »

Company Comment

Would A Combined AstraZeneca plc/Pfizer Inc. Be Worth Owning?

| Mark Stones

AstraZeneca plc's (LON: AZN) strengths as a separate entity won't be best harnessed by Pfizer Inc. (NYSE:PFE)

Read more »